Evidence map›Paper›PMID 33941488›Full record

ArticleDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver2021

Italian association for the study of the liver position statement on SARS-CoV2 vaccination.

Francesco Paolo Russo, Salvatore Piano, Raffaele Bruno, Patrizia Burra, Massimo Puoti, Mario Masarone, Sara Montagnese, Francesca Romana Ponziani, Salvatore Petta, Alessio Aghemo and 1 more

Registry-linked trialOpen access · bronzeAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05532592 (Investigation on the Hesitancy of COVID-19 Vaccination Among Liver Transplant Recipients in China), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05532592 completednot on this mapstarted 2022, after this paper: background citation

Investigation on the Hesitancy of COVID-19 Vaccination Among Liver Transplant Recipients in China

TypeobservationalSponsorRenJi HospitalRan2022 to 2022Enrolled449ConditionsVaccine HesitancyArmsPerceptions and attitudes towards COVID-19 and COVID-19 vaccine
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. [Rapid guideline for COVID-19 vaccination in patients with chronic liver diseases, hepatolbiliary malignancy and liver transplant].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
    Guideline
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Sars-Cov-2 vaccination in liver transplant recipients: The 'holy grail' in a hostile environment.Liver international : official journal of the International Association for the Study of the Liver · 2022
    Article
  8. Ethical review of COVID-19 vaccination requirements for transplant center staff and patients.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Francesco Paolo RussoDepartment of Surgery, University Hospital Padua, Oncology and Gastroenterology, Italy. Electronic address: info@webaisf.org.
Salvatore PianoDepartment of Medicine, University Hospital Padua, Italy.
Raffaele BrunoDepartment of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Italy.
Patrizia BurraDepartment of Surgery, University Hospital Padua, Oncology and Gastroenterology, Italy.
Massimo PuotiInfectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Italy.
Mario MasaroneDepartment of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Italy.
Sara MontagneseDepartment of Medicine, University Hospital Padua, Italy.
Francesca Romana PonzianiInternal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Salvatore PettaDipartimento Biomedico di Medicina Interna e Specialistica Di.Bi.M.I.S, University of Palermo, Italy.
Alessio AghemoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; Humanitas Research Hospital IRCCS, Rozzano, Italy.
Italian Association for the Study of the Liver
University of Padua · ITAgostino Gemelli University Polyclinic · ITAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITHumanitas University · ITUniversity of Palermo · ITUniversity of Pavia · ITUniversity of Salerno · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver disease, a possible priority for vaccination for this category of patients.

Indexed as

COVID-19COVID-19 VaccinesImmunization ProgramsLiver DiseasesHumansImmunosuppressive AgentsItalyLiver TransplantationPatient SafetyPatient SelectionRisk AdjustmentRisk AssessmentSARS-CoV-2Transplant RecipientsTreatment OutcomeCOVID-19 VaccinesImmunosuppressive AgentsChronic liver diseaseSars-CoV-2Vaccination

Identifiers

PMID33941488
PMCPMC8086184
OpenAlexW3158656170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.